Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure
Asian Markets End Year on AI Optimism as Precious Metals and Currencies Shine
U.S. Stock Index Futures Steady as Markets Await Fed Policy Clues in Holiday-Thinned Trade
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside
Gold Prices Rebound in Europe as Geopolitical Tensions and Fed Outlook Support Bullion
South Korean Won Slides Despite Government Efforts to Stabilize Currency Markets
China Manufacturing PMI Rebounds in December, Offering Boost to Economic Growth Outlook
Oil Prices Slide in 2025 as Oversupply and Geopolitical Risks Shape Market Outlook
Asia Manufacturing PMI Rebounds as Exports and Tech Demand Drive Growth into 2026
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure
USDA $12 Billion Farm Aid Program Draws Mixed Reactions from Row Crop Farmers
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 



